Medipost Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 334

Employees

  • Stock Symbol
  • 078160

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $5.77
  • (As of Friday Closing)

Medipost General Information

Description

Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 21 Daewangpangyo-ro 644
  • Bundang-gu
  • Seongnam, Gyeonggi-do 137-874
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Corporate Office
  • 21 Daewangpangyo-ro 644
  • Bundang-gu
  • Seongnam, Gyeonggi-do 137-874
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medipost Stock Performance

As of 20-Nov-2026, Medipost’s stock price is $5.77. Its current market cap is $226M with 39.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.77 $6.03 $5.02 - $19.74 $226M 39.1M 50.1K -$0.46

Medipost Financials Summary

As of 30-Jun-2026, Medipost has a trailing 12-month revenue of $51.6M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 186,068 477,240 200,064 151,392
Revenue 51,572 51,757 51,785 52,501
EBITDA (12,042) (57,252) (43,835) 10,815
Net Income (15,900) (60,007) (45,825) 4,467
Total Assets 362,199 299,686 281,260 348,723
Total Debt 103,724 28,055 7,571 9,035
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Medipost Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medipost‘s full profile, request access.

Request a free trial

Medipost Patents

Medipost Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024543218-A Composition for preventing or treating lung disease comprising cd47-overexpressing mesenchymal stem cells Pending 01-Dec-2021
AU-2022403380-A1 Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells Pending 01-Dec-2021
CA-3239499-A1 Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells Pending 01-Dec-2021
EP-4442263-A1 Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells Pending 01-Dec-2021
EP-4442263-A4 Composition for preventing or treating lung diseases containing cd47-overexpressing mesenchymal stem cells Pending 01-Dec-2021 A61K35/28
To view Medipost’s complete patent history, request access »

Medipost Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medipost Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Medipost‘s full profile, request access.

Request a free trial

Medipost Investments & Acquisitions (2)

Medipost’s most recent deal was a Secondary Transaction - Private with OmniaBio for . The deal was made on 31-May-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OmniaBio 31-May-2022 Secondary Transaction - Private Other Pharmaceuticals and Biotechnology
Immunique 01-Apr-2021 Merger/Acquisition Drug Discovery
To view Medipost’s complete investments and acquisitions history, request access »

Medipost ESG

Risk Overview

Risk Rating

Updated October, 31, 2024

28.19 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,201

Rank

Percentile

Healthcare

Industry

of 592

Rank

Percentile

Medical Services

Subindustry

of 104

Rank

Percentile

To view Medipost’s complete esg history, request access »

Medipost Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Immunique Seongnam, South Korea 2021

Medipost FAQs

  • When was Medipost founded?

    Medipost was founded in 2000.

  • Where is Medipost headquartered?

    Medipost is headquartered in Seongnam, South Korea.

  • What is the size of Medipost?

    Medipost has 334 total employees.

  • What industry is Medipost in?

    Medipost’s primary industry is Biotechnology.

  • Is Medipost a private or public company?

    Medipost is a Public company.

  • What is Medipost’s stock symbol?

    The ticker symbol for Medipost is 078160.

  • What is the current stock price of Medipost?

    As of 20-Nov-2026 the stock price of Medipost is $5.77.

  • What is the current market cap of Medipost?

    The current market capitalization of Medipost is $226M.

  • What is Medipost’s current revenue?

    The trailing twelve month revenue for Medipost is $51.6M.

  • What is Medipost’s annual earnings per share (EPS)?

    Medipost’s EPS for 12 months was -$0.46.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process